Antibodies for binding to cd80
By developing an antigen-binding protein that can bind to CD80 and block PD-L1, the problem of insufficient CD80 co-stimulation and PD-L1 checkpoint pathway regulation in existing technologies has been solved, achieving effective regulation and immunosuppression of the immune response, which is suitable for the treatment of autoimmune diseases.
CN122459342APending Publication Date: 2026-07-24MONASH UNIV +1
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- MONASH UNIV
- Filing Date
- 2024-11-01
- Publication Date
- 2026-07-24
AI Technical Summary
Technical Problem
Existing technologies are unable to effectively modulate CD80 co-stimulation and the PD-L1 checkpoint pathway, resulting in poor treatment outcomes for autoimmune diseases.
Method used
Develop an antigen-binding protein that can bind to CD80, block CD80:PD-L1 interaction, inhibit the binding of PD-L1 to CD80, and not inhibit the binding of CD28 or CD86 after binding to CD80.
Benefits of technology
By blocking the CD80:PD-L1 interaction, the immune response is regulated, providing a more effective immunosuppressive effect, which is suitable for the treatment of autoimmune diseases.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure FT_1 
Figure FT_2 
Figure FT_3
Abstract
The present invention relates to antigen-binding proteins, related fragments thereof, for binding to CD80, and their use for treating various conditions such as inflammation and autoimmunity.
Need to check novelty before this filing date? Find Prior Art
Citation Information
Patent Citations
Antibodies for binding to CD80
AU2023903540
Fc variants with altered binding to FcRn
US20070135620A1
Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
US4554101A
Polypeptide variants
US6194551B1
Polypeptide variants with altered effector function
US6737056B1